Genomic Valley Biotech P/E Ratio
Current P/E Ratio
469.3
High Valuation
Very High - High growth expectations or significantly overvalued
Genomic Valley Biotech P/E ratio. Genomic Valley Biotech (GVBL) P/E ratio is 469.3 (High), EPS (TTM) ₹0.10, current price ₹46.93 on BSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see GVBL screener.
Current Valuation Metrics
P/E Ratio
469.3
Current Price
₹46.93
EPS (TTM)
₹0.10
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
52.19
Sector Median
29.6
Sector Rank
#11 of 256
Sector Percentile
4.3%
GVBL P/E Ratio — Valuation Signal & Historical Context
Genomic Valley Biotech P/E 469.3 — signal: Overvalued. Also explore GVBL share price data to track price trends across different timeframes.
- Stock appears overvalued with PE of 469.3, suggesting caution for new investments
- Trading at premium to sector average PE of 52.19
GVBL vs Healthcare Peers — P/E Ratio Comparison
Genomic Valley Biotech P/E 469.3 vs Healthcare average 52.19, median 29.6 — range 2.0–733.0.
Sector Average
52.19
Sector Median
29.6
Lowest P/E
2.0
Highest P/E
733.0
Companies
256
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.0 | ₹72 | Low |
| Brooks Laboratories | BROOKS | 2.6 | ₹206 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.3 | ₹54 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.1 | ₹6,355 | Low |
| Dipna Pharmachem | DPL | 4.5 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.7 | ₹82 | Low |
| Royal Sense | ROYAL | 4.8 | ₹34 | Low |
| Star Imaging And Path Lab | STARIMAGIN | 5.3 | ₹110 | Low |
| Kabra Drugs | KABRADG | 6.3 | ₹49 | Low |